LONDON, Nov. 2, 2017 /PRNewswire/ -- According to Stratistics MRC, the Global Viral Inactivation Market is accounted for $1.99 billion in 2016 and expected to grow at a CAGR of 14.9% to reach $5.29 billion by 2023. Factors such as rapid growth in pharmaceutical and biotechnology industries, strong R&D investments in the life sciences industry, high incidence of chronic diseases and increasing number of new drug launches are driving the market growth. However, the high cost of biologics and biosimilars products, development of expensive equipment for viral inactivation are inhibiting the marketspace.
Read the full report: https://www.reportlinker.com/p05169999
Based on method, the Alkylating agent method segment is considered as the robust & efficient method for inactivation of variety of enveloped viruses. Alkylating agents are monofunctional or bifunctional. Two mechanisms exist for viral inactivation with alkylating agents. One mechanism involves the modification of proteins, which would cause inhibition of viral cell entry or the release of the genome. Also, Formalin and ?-propiolactone (?-PL) are used for inactivation of viruses via chemical reaction along with viral capsid proteins and nucleic acids. Alkylating agents permeate the protein capsid of viruses and chemically inactivate the nucleic acid. The alkylating agent N-acetyl-aziridine is a virus inactivate that has been used in vaccine preparation.
Based on product, the usage of kits and reagents has increased tremendously. Two nucleic acid extraction buffers available commercially are used to inactivate the viral stocks. These are TRIzol® LS reagent (Invitrogen Corp.) and AVL Buffer from the Qiamp viral RNA mini kit (Qiagen). North America has dominated the market during the forecast period due to adoption of many methods by blood testing centre. According to the FDA, 41 novel drugs were approved. Increase in funding has also resulted in growth in number of FDA approvals over the recent years.
Some of the key players in Global Viral Inactivation market are Macopharma SA, Charles River Laboratories International, Inc., Clean Cells Inc., Danaher Corporation, Merck KGAA, Parker Hannifin Corporation, Rad Source Technologies, Inc., SGS SA, Sartorius AG, Texcell, Inc., Viral Inactivated Plasma Systems SA, Wuxi Pharmatech (Cayman) Inc., Shandong Weigao Group Medical Polymer Company Limited, Cerus Corporation, Terumo BCT, Inc, BioReliance, Thermo Fisher Scientific Inc. and Macopharma SA.
Applications Covered:
• Stem cell products
• Cellular & Gene therapy products
• Blood & Blood tissue products
• Vaccines & Therapeutics
• Tissues & Tissue products
Products Covered:
• Viral inactivation accessories
• Systems and Services
• Kits & Reagents
Methods Covered:
• pH Concentration method
• Alkylating agent method
• Solvent detergent method
• Pasteurization
• Radiation method
• Other Methods
End Users Covered:
• Blood banks and Hospitals
• Academic research institutes
• Pharmaceutical and Biotechnology companies
• Contract Research Organizations
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Read the full report: https://www.reportlinker.com/p05169999
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
https://www.reportlinker.com
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
View original content:http://www.prnewswire.com/news-releases/the-global-viral-inactivation-market-is-accounted-for-199-billion-in-2016-and-expected-to-grow-at-a-cagr-of-149-to-reach-529-billion-by-2023-300548946.html
SOURCE Reportlinker
